In an era of health reform, diagnostic technologies that focus on prevention and test the viability of expensive treatment options are becoming increasingly valuable to health providers, payers, and patients. Historically, investment in this sector has not seen the vigor demonstrated with medical devices or biotech innovations. However, in today’s environment, diagnostics are becoming attractive opportunities for companies looking for collaborations or acquisitions as well as investors looking for cutting-edge technologies, all creating a robust industry on the brink of breaking through to the mainstream.
In this presentation, panelists will:
- Provide insight on the diagnostic industry on a local and national level
- Discuss key elements that are reviewed when assessing start-up opportunities
- Discuss where opportunities exist for maximizing profits
- Provide new strategies for raising funds in this dynamic marketplace
Panelist:
Ronald S. Eppen, Partner, Foley & Lardner LLP
Lucy Lu, Vice President of Business Development, Crescendo Bioscience
Natasha Paul, Ph.D., Scientific Investigator, TriLink Biotechnologies, Inc.
Jon Vance, Director, Avondale Partners, LLC
Related Insights
December 8, 2025
Foley Viewpoints
2026 Outlook: AI, IPOs, and the New “Normal” in Venture & Private Equity
Key Takeaways The 2026 outlook for market activity is cautiously optimistic amid ongoing challenges.Private equity firms are shifting to…
December 8, 2025
Labor & Employment Law Perspectives
Colorado Adds New NICU Leave Under FAMLI: What Employers Should Know
Colorado’s Family and Medical Leave Insurance (FAMLI) program has provided employees with paid leave for major life events since 2024,…
December 8, 2025
Labor & Employment Law Perspectives
The Post-Shutdown Compliance Crunch: Preparing for Agency Action
The longest federal government shutdown in U.S. history has ended, and employers must now refocus their attention on agency actions and…